Resistance of Cancer Cells to CTL-Mediated Immunotherapy

1. Front Matter

   Pages i-xix

   PDF

2. Factors Regulating Resistance to CTL Cytotoxicity

   1. Front Matter

      Pages 1-1

      PDF

   2. Resistance of Cancer Stem Cells to Cell-Mediated Immune Responses

      • Veronica Catalano, Cecilia Eleuteri, Gaia Campoccia, Gianluca Giacobini, Mariangela Zane, Giorgio Stassi et al.

      Pages 3-29

   3. Role of Co-inhibitory Molecules in Tumor Escape from CTL Attack

      • Wieger J. Norde, Willemijn Hobo, Harry Dolstra

      Pages 31-58

   4. Role of the Non-classical HLA Class I Antigens for Immune Escape

      • Barbara Seliger, Simon Jasinski-Bergner

      Pages 59-72

   5. Integrins: Friends or Foes of Antitumor Cytotoxic T Lymphocyte Response

      • Marie Boutet, Stephanie Cognac, Fathia Mami-Chouaib

      Pages 73-89

   6. Cytotoxic T Lymphocytes and Their Granzymes: An Overview

      • Janis Noonan, Brona M. Murphy

      Pages 91-112

3. Influence of the Tumor Microenvironment on the Resistance to CTL Cytotoxicity

   1. Front Matter

      Pages 113-113

      PDF

   2. Hypoxia: A Formidable Saboteur of the Anti-tumor Response

      • Meriem Hasmim, Yosra Messai, Stéphane Terry, Bassam Janji, Muhammad Zaeem Noman, Salem Chouaib

      Pages 115-142

   3. Mechanisms and Modulation of Tumor Microenvironment-Induced Immune Resistance

      • Tuna Mutis, Niels W. C. J. van de Donk, Richard W. J. Groen

      Pages 143-158

   4. Evasion of Cytotoxic Lymphocyte and Pulmonary Macrophage-Mediated Immune Responses in Lung Cancer

      • Sandra Hodge, Greg Hodge

      Pages 159-174

4. Resistance to Death Ligands-Mediated Apoptosis and Sensitization

   1. Front Matter

      Pages 175-175

      PDF

   2. Sensitization of Immune-Resistant Tumor Cells to CTL-Mediated Apoptosis via Interference at the Dysregulated NF-κB/Snail/YY1/PI3K/RKIP/PTEN Resistant Loop

      • Benjamin Bonavida

      Pages 177-208

   3. Overcoming Cancer Cell Resistance to Death Receptor Targeted Therapies

      • Julianne D. Twomey, William Hallett, Baolin Zhang

      Pages 209-233

   4. Pancreatic Cancer Resistance to TRAIL Therapy: Regulators of the Death Inducing Signaling Complex

      • Yabing Chen, Kaiyu Yuan, Jay McDonald

      Pages 235-265

   5. Epithelial Mesenchymal Transition Influence on CTL Activity

      • Wilfried Engl, Virgile Viasnoff, Jean Paul Thiery

      Pages 267-284

5. Future Directions and Challenges

   1. Front Matter

      Pages 285-285

      PDF

   2. Cancer Induced Immunosuppression and Its Modulation by Signal Inhibitors

      • Yutaka Kawakami, Li Qian, Naoshi Kawamura, Junichiro Miyazaki, Kinya Tsubota, Tomonari Kinoshita et al.

      Pages 287-301

   3. Quality of CTL Therapies: A Changing Landscape

      • Krishnamurthy Thyagarajan, Shilpak Chatterjee, Pravin Kesarwani, Michael I. Nishimura, Shikhar Mehrotra

      Pages 303-349

6. ERRATUM TO: Integrins: Friends or Foes of Antitumor Cytotoxic T Lymphocyte Response

   • Marie Boutet, Stephanie Cognac, Fathia Mami-Chouaib

   Pages E1-E1

This comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more.

• HDAC inhibitors
• Proteasome inhibitors
• apoptosis
• cytotoxic t lymphocytes
• drug-resistant cancer cells
• epitopes
• antibacterial drug resistance

• Department of Microbiology, Immunology a, University of California at Los Angeles,, Los Angeles, USA

  Benjamin Bonavida

• Institut Gustave Roussy, Villejuif, France

  Salem Chouaib

Benjamin Bonavida, Ph.D., is Professor, UCLA David Geffen School of Medicine for the Department of Microbiology, Immunology & Molecular Genetics. He is also Member, Department of Defense Congressionally Directed Medical Research Program, Member, National Cancer Institute SPORE Program, Member, International Scientific Advisory Board of the Israel Cancer Research Foundation, among other accomplishments. He is currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. He has published over 450 papers and reviews, has received more than 7,980 citations, and has edited four Springer volumes.

Salem Chouaib, Ph.D., is Head, Cancer Immunology Division at Institut Gustave Roussy. His research focuses on augmenting cytotoxic T cell immunity and studies how tumors evade the immune system. Dr. Chouaib has published more than 239 scientific papers and reviews, and has received more than 5,490 citations.